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Abstract
Francisella tularensisis a facultative intracellular pathogen, and is the causative agent of a
fatal human disease known as tularemia. F. tularensis is classified as a Category A Bio-
threat agent by the CDC based on its use in bioweapon programs by several countries in
the past and its potential to be used as an agent of bioterrorism. No licensed vaccine is
currently available for prevention of tularemia. In this study, we used a novel approach for
development of a multivalent subunit vaccine against tularemia by using an efficient
tobacco mosaic virus (TMV) based delivery platform. The multivalent subunit vaccine was
formulated to contain a combination of F. tularensis protective antigens: OmpA-like protein
(OmpA), chaperone protein DnaK and lipoprotein Tul4 from the highly virulent F. tularen-
sisSchuS4 strain. Two different vaccine formulations and immunization schedules were
used. The immunized mice were challenged with lethal (10xLD100) doses of F. tularen-
sisLVS on day 28 of the primary immunization and observed daily for morbidity and mortal-
ity. Results from this study demonstrate that TMV can be used as a carrier for effective
delivery of multiple F. tularensisantigens. TMV-conjugate vaccine formulations are safe and
multiple doses can be administered without causing any adverse reactions in immunized
mice. Immunization with TMV-conjugated F. tularensisproteins induced a strong humoral
immune response and protected mice against respiratory challenges with very high doses
of F. tularensis LVS. This study provides a proof-of-concept that TMV can serve as a suit-
able platform for simultaneous delivery of multiple protective antigens of F. tularensis.
Refinement of vaccine formulations coupled with TMV-targeting strategies developed in
this study will provide a platform for development of an effective tularemia subunit vaccine
as well as a vaccination approach that may broadly be applicable to many other bacterial
pathogens.
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Introduction
Francisella tularensis is the causative agent of a fatal human disease known as tularemia [1,2].
Francisella is divided into two species; tularensis and philomiragia [3,4]. There are four subspe-
cies of F. tularensis: tularensis (also known as F. tularensis type A), novicida,mediasiatica and
holarctica (also known as F. tularensis type B) [5]. Of these, only F. tularensis subsp. tularensis
and subsp. holarctica can cause disease in immunocompetent humans. F. tularensis SchuS4
strain is a representative of F. tularensis subspecies tularensis. F tularensis has been classified as
Tier 1 Category A Select Agent, which is the highest priority category on the list of CDC
among other potential Biothreat agents [6]. The bioweapon potential of F. tularensis is on
account of its extreme virulence, low infectious dose, ease of aerosol dissemination and capacity
to cause severe illness and death in a very short period of time [7]. No licensed vaccine is cur-
rently available in the USA for prevention of tularemia [8,9]. Considering the bioweapon
potential of F. tularensis and repercussions of 2001 anthrax attack in the USA, there has been
an increased interest in development of vaccine and effective countermeasures against bioter-
ror agents. An ideal solution for prevention of tularemia occurring naturally or consequent to
the use of Francisella as a bioweapon or an act of bioterrorism is to develop a safe and effective
vaccine capable of inducing long lasting protection in a relatively short period of time [10].
In the last 100 years since the discovery of F. tularensis, three broad approaches comprising
of killed whole cell, live attenuated and subunit vaccines have been employed for vaccine devel-
opment, but none of these have been successful [11]. Although, a Live Vaccine Strain (LVS)
developed from the Russian strain F. holarctica S15 is protective, it retains residual virulence in
humans when immunized via aerosol or intranasal (i.n.) routes. Due to adverse reactions and
residual virulence, LVS is not approved by the FDA for mass immunizations in the USA.
Attenuated mutants of F. tularensis SchuS4 or the LVS containing single gene deletions have
shown better protective efficacy in mouse models of tularemia [12,13,14,15,16,17]. However,
these mutants pose a potential possibility of reversion to fully virulent forms. Inactivated LVS
or SchuS4 tularemia vaccines have demonstrated poor protective efficacies against challenges
with virulent F. tularensis [11,18,19,20]. Several efforts to develop subunit tularemia vaccine
have met with limited success. The primary shortcomings have been the constituents of sub-
unit vaccines which contained either a single surface associated antigenic component of F.
tularensis such as LPS or specific immunoreactive proteins such as GroEL, DnaK, FopA, KatG
or a F. tularensis specific lipoprotein Tul4 [21,22,23,24,25,26,27,28]. Despite being immuno-
genic, these single subunit vaccines failed to provide protection against virulent F. tularensis
strains. The possible explanations for their failure could be that single proteins are not suffi-
cient or that the vaccine formulations lacked right combination of antigens required for induc-
tion of a protective immune response. The challenges thus far in development of multivalent
subunit vaccines have been the availability of suitable approaches for consistent preparation
and efficient delivery of multiple antigens through mucosal routes.
The goal of this study was to explore vaccine potential and preclinical development of a
multivalent subunit vaccine against tularemia using an efficient TMV based delivery platform.
The premise behind utilizing a novel TMV-conjugated vaccination strategy is founded on the
proven efficacy of TMV vaccines in stimulating robust humoral and cellular immune response
without the requirement of an additional adjuvant [29]. TMV as an antigen carrier provides
two important functions: 1) because of the virus architecture and size, TMV provides for active
and robust uptake by dendritic cell and activation of key surface markers in vitro and in vivo
resulting in effective antigen presentation [30,31]. 2), TMV provides adjuvant effects, either
because of the repetitive antigen display that mimics virus surfaces which is important for
generation of potent antibody responses, or because of the presence of virus RNA (albeit
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non-functional) which is important for inducing cell mediated immunity (or both). Conjugat-
ing an immunogenic subunit vaccine protein to the surface of TMV promotes antigen uptake
and improves an antiviral response against the subunit protein. A recent study demonstrated
single dose potency of a TMV-hemagglutinin (TMV-HA) vaccine in an influenza challenge
model without the need for an adjuvant [32]. Because TMV is not a human pathogen [33],
TMV is inherently safe. In addition, TMV does not show evidence of neutralizing antibodies in
individuals, so it can be used repeatedly for boosting [31,32]. These characteristics of TMV are
extremely important in producing a safe, effective vaccine that can stimulate protection against
F. tularensis challenge.
We investigated the vaccine potential of a multivalent tularemia vaccine by chemically con-
jugating TMV to multiple protective antigens of F. tularensis. We used purified recombinant
proteins DnaK (FTT1269c), OmpA (FTT0831c) and Tul4 (FTT0901) of F. tularensis SchuS4
and determined the vaccine potential of TMV-F. tularensis protein conjugate vaccine. When
used in vaccine formulations, both DnaK and Tul4 have been shown to render some degree of
protection against F. tularensis LVS in vaccinated mice [34,35]. This was the rationale for inclu-
sion of these proteins in our studies to investigate the efficacy of TMV-conjugate vaccine. In
addition to DnaK and Tul4, we also included OmpA-like protein in the conjugate cocktail
based on its surface exposed structures, role in innate immune subversion both in vitro and in
vivo [13,36,37] and exclusive reactivity of this protein with the serum from successfully vacci-
nated individuals as well as mice [38,39,40,41]. This study demonstrates that TMV effectively
delivers multiple F. tularensis antigens to induce protective immune responses in mouse model
of respiratory tularemia and provide a proof-of-concept for the feasibility of TMV as a carrier
for bacterial antigenic proteins.
Materials and Methods
Ethics Statement
This study was carried out in strict accordance with the recommendations and guidelines of
National Council for Research (NCR) for care and use of animals. All the animal experiments
were conducted in the centralized Animal Resources Facilities of Albany Medical College and
New York Medical College licensed by the USDA and the NYS Department of Health, Division
of Laboratories and Research and accredited by the American Association for the Accreditation
of Laboratory Care. The use of animals and protocols were approved by the Institutional Ani-
mal Care and Use Committee (IACUC) of New York Medical College (Protocol Number 30-2-
0414H). Mice were administered an anesthetic cocktail consisting of ketamine (5 mg/kg) and
xylazine (4 mg/kg) and underwent experimental manipulation only after they failed to exhibit
a toe pinch reflex. Mice exhibiting more than 20% weight loss, anorexia, dehydration and
impairment of mobility were removed from the study and euthanized by approved means.
Humane endpoints were also necessary for mice which survived at the conclusion of the exper-
iment. Mice were administered an anesthetic cocktail of ketamine and xylazine intraperitone-
ally and then euthanized via cervical dislocation followed by cardiac puncture, a method that is
consistent with recommendations of the Panel on Euthanasia of the American Veterinary
Medical Association. In all experimental procedures, efforts were made to minimize pain and
suffering.
Bacterial Strains
F. tularensis LVS (American Type Culture, ATCC 29684; Rockville, MD) used in this study
was obtained from BEI Resources, Manassas, VA. F. tularensis LVS was grown on Mueller-
Hinton (MH) chocolate agar plates (BD Biosciences, San Jose, CA) or MH-broth (MHB; BD
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Biosciences, San Jose, CA) supplemented with 0.021% w/v, Anhydrous Calcium chloride,
0.000138% w/v Hydrous Magnesium Chloride, 0.00021% w/v 10% Glucose, 10% v/v, 2.5% Fer-
ric Pyrophosphate, 2.5% v/v Isovitalex (BD Biosciences, San Jose, CA). The active mid-log
phase bacteria grown in MHB were harvested, aliquoted into sterile 1.5 mL cryovials and stored
at −80°C for further use.
Expression and Purification of Recombinant Proteins
The dnaK gene (FTT1269c) of F. tularensis SchuS4 cloned in E. coli expression vector
pDSET17 was obtained from Harvard Institute of Proteomics. The genes of F. tularensis
SchuS4 encoding for OmpA (FTT0831c) and Tul4 (FTT0901) were cloned into the pPROEX
Htb vector (Invitrogen). The plasmids were transformed into E. coli (BL21/XL10 Gold) strain,
induced for expression by IPTG, and purified by metal affinity chromatography. The purity of
the proteins was confirmed by SDS-PAGE and western blot analysis using anti-6His
antibodies.
Purification of TMV-Lysine Virus Particles
TMV was genetically engineered to express coat protein containing a surface exposed lysine
[42]. Infectious TMV RNA was inoculated onto 30 day Nicotiana benthamiana plants, and
harvested for virus 10 days later according to previously described protocols [42,43]. Briefly,
plant tissue was homogenized in 0.86M NaCl, 0.04% w/v sodium metabisulfite (0.5 g of tissue/
ml of buffer), adjusted to pH 5.0, heated to 47°C for 5 min, and then chilled to 4°C. Homoge-
nate was centrifuged at 6000 × g for 20 min, and then the clarified supernatant was precipitated
with 5% Poly Ethylene Glycol (PEG) 8000 at 4°C, and spun at 12,000 × g for 10 min at 4°C to
recover the virus. PEG pellets were resuspended in PBS, and re-precipitated with PEG a second
time. Final PEG pellets were resuspended in PBS at 1:10th homogenization volume, and final
protein concentration was measured by Bicinchoninic Acid (BCA). Purity was determined
(typically>98%) by SDS-PAGE.
Conjugation of F. tularensis Proteins to TMV
In order to use TMV as a platform, recombinant F. tularensis proteins were chemically conju-
gated to decorate the surface of TMV. For conjugation reaction, purified–TMV-Lysine and
individual purified recombinant proteins OmpA, DnaK, and Tul4 were mixed at 1:1 molar
ratios. The conjugation reaction was carried out by adding 5mM of 1- Ethyl-3-(3-dimethylami-
nopropyl) carbodiimide (EDC) and 1mM of N-hydroxysuccinimide (NHS). The conjugation
mixture was then incubated for various time intervals to achieve maximum conjugation effi-
ciency. The reaction time that generated the least amount of free protein (2 hours) was used in
scale up conjugation reactions (5mg antigen with 5mg TMV) for vaccine potency testing. For
the TMVmonoconjugate vaccine, where all three proteins were reacted together onto the same
virus, each protein was mixed with TMV at a 30% molar ratio (1x TMV, 0.3x each protein)
and reacted for 2 hours to ensure complete conjugation. The efficiency and successful conjuga-
tion of recombinant proteins of F. tularensis SchuS4 to the TMV virion was determined by
8–16% Tris-Glycine SDS-PAGE.
Safety, Immunogenicity and Protective Efficacy of TMV-Conjugate
Vaccines
Mice. Wild-type C57BL/6 mice were purchased from Charles River Laboratories, NY. Six
to eight weeks old female mice were used in all experiments. All mice were maintained in
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environmentally controlled and pathogen-free animal facility of New York Medical College.
All mice that were to be immunized or challenged were anesthetized by i. p. injection of a cock-
tail of Ketamine and xylazine to facilitate delivery of the inoculum to the respiratory compart-
ment. All mice experiments were performed according to the guidelines and protocols
approved by the IACUC at New York Medical College.
Vaccine formulations. Two different vaccine formulations were used. In the first formula-
tion, all three recombinant proteins OmpA, DnaK and Tul4 were conjugated to a single TMV
virion. This vaccine formulation was designated as TMV-monoconjugate vaccine. Mice were
immunized with 60μg of TMVmonoconjugate vaccine (~30μg TMV and 30μg of recombinant
proteins). In the second vaccine formulation, each individual protein was conjugated to the
TMV individually (10μg TMV + 10μg recombinant protein) and then each of the three TMV-
protein conjugates were mixed in equal concentrations [20μg x 3 = 60μg (30μg TMV + 30μg
recombinant proteins)]. This formulation was designated as TMV-multiconjugate vaccine
(Fig 1). Based on the amount of TMV that each of the vaccinated mouse received (30μg), mice
inoculated with an 30μg of TMV served as controls.
Immunization schedules. Two different immunization schedules were used. In the first
immunization schedule (Schedule I) C57BL/6 mice were immunized intranasally (i.n.) with
60μg of TMVmonoconjugate or TMV-multiconjugate vaccine. Mice were immunized i.n. with
30μl (15μl/ nostril) volume of each of the vaccine formulation or the TMV controls. Booster
vaccinations using dosages similar to the primary immunization were administered on days 7
and 14 after the primary immunization. Mice receiving 30μg of TMV alone and administered
in a fashion similar to the vaccine groups were kept as controls (Fig 2A). Mice were monitored
for any adverse reaction following each vaccine administration.
Mice immunized employing schedule II were vaccinated only with TMV-multiconjugate
vaccine. C57BL/6 mice were immunized i.n. on day 0, 5 and 14 with a total of 60μg of TMV-
multiconjugate vaccine. These mice also received similar vaccination dose of TMV-multiconju-
gate vaccine subcutaneously (s.c.) on days 3, 7 and 14. Control mice received 30 μg of TMV
Fig 1. Vaccine Formulations. Two different vaccine formulations were used. In the first vaccine formulation all
three recombinant proteins OmpA, DnaK and Tul4 were conjugated to a single TMV virion (TMV-monoconjugate
vaccine). The second vaccine formulation contained each recombinant protein of F. tularensis conjugated
individually to TMV and then mixed in equal concentrations to generate a TMV-multiconjugate vaccine.
doi:10.1371/journal.pone.0130858.g001
Multivalent Vaccine for Prevention of Tularemia
PLOS ONE | DOI:10.1371/journal.pone.0130858 June 22, 2015 5 / 22
following the immunization schedule identical to those for the TMV-multiconjugate vaccine
group (Fig 2B). All vaccinated and control mice were monitored for any adverse reaction fol-
lowing each primary and booster immunizations. All the vaccinated mice were bled periodi-
cally to collect serum to determine antibody responses. The Schedule I immunizations were
based on a number of vaccination studies using inactivated or subunit vaccines of F. tularensis
[18,34,44]. The aggressive immunization strategy (Schedule II) was based on our recent report
indicating that alternate i.n. and s.c. booster immunizations enhanced protection in immu-
nized mice against an i.n. challenge with F. tularensis SchuS4 strain [45] and the vaccination
schedule recommended for commercially available oral typhoid vaccine, Vivotif.
Determination of antibody responses in immunized mice. For determination of anti—
F. tularensis antibody levels in vaccinated mice following the immunization schedules
described above, ELISA was performed using lysates made from F. tularensis SchuS4 or LVS
strains. The formalin fixed SchuS4 was obtained from BEI Resources, Manassas, VA. For
ELISA 96-well microtiter plates were coated with 1×107 CFU/ml of either F. tularensis SchuS4
or LVS in bicarbonate buffer. F. tularensis-specific antibody levels for total IgG, IgG1, IgG2a
and IgG2b in serum samples collected from immunized mice on 28 post-immunization were
determined by ELISA. Serum collected from naïve mice or mice that received TMV were used
as controls. To determine the level of antibodies induced against each individual protein of the
TMV-monoconjugate or the TMV-multiconjugate vaccine each individual ELISA was per-
formed by coating plates with 1μg of each individual purified recombinant OmpA, DnaK and
Tul4 proteins. The protein specific total IgG levels were determined in serum from vaccinated
mice collected on day 28 post-immunization. Antibody titers were calculated from linear
Fig 2. Immunization Schedules I and II. (A) C57BL/6 mice were immunized intranasally (i.n.) either with
TMV-monoconjugate (60 μg/mouse) or TMV-multiconjugate vaccine formulations (20 μg each of
OmpA-TMV; DnaK-TMV and Tul4-TMV conjugates. Total 60 μg/mouse) and booster vaccinations were
administered i.n. using dosages similar to those for primary immunization on days 7 and 14 of the post-
primary immunization (Schedule I). (B) Alternatively, mice were administered TMV-multiconjugate vaccines
with booster immunizations i.n. on day 5 and 14 and subcutaneously (s.c.) on days 7 and 14 post-primary
immunization (Schedule II). The dosages used were similar to those described for TMV-multiconjugate
vaccine inA. Mice inoculated with TMV (30 μg/mouse) in a manner similar to the vaccinated groups were
kept as controls.
doi:10.1371/journal.pone.0130858.g002
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regression curves as the inverse of the serum dilution that showed an OD450 value 2.5 times
above the controls, and expressed as Log10 values.
To determine if antibodies generated in vaccinated mice are capable of identifying native
and recombinant Francisella OmpA, DnaK and Tul4 proteins, western blot analysis was per-
formed. Serum collected on day 28 from mice immunized with TMV-multiconjugate vaccine
utilizing Schedule II was used for western blot analysis. Eight micrograms each of F. tularensis
LVS and SchuS4 lysates were resolved on SDS-PAGE, transferred to nitrocellulose membrane
and blotted against pooled serum from immunized mice. Serum collected from mice immu-
nized with TMV was used as a control. To determine if antibodies from immunized mice
reacted with recombinant proteins as well, 1μg of purified recombinant proteins were used in
western blot analysis.
Challenge studies. To determine the protective efficacy of TMV-vaccine against a high
challenge dose of LVS, all immunized mice were challenged i.n. with 10×LD100 (1×10
5 CFU)
dose of F.tularensis LVS on day 28 of the primary immunization. The actual numbers of F.
tularensis inoculated into mice at that time of challenge were confirmed by plating serial dilu-
tions on MH-chocolate agar plates and counting the colonies 48 hours later.
Post-challenge studies. All the challenged mice were observed daily for signs of morbidity
and/or mortality for a period of 21 days. To monitor the progression of infection all challenged
mice were weighed every day until they regained their original body weight.
Statistical Analysis
All data for antibody levels of immunized mice were statistically analyzed using InStat program
(Graph-Pad Software). The results were expressed as Means ± S.D. The survivals data were
expressed as Kaplan-Meier survival curves and statistical significance for survival results were
evaluated by analyzing the mean time to death by the Log-Rank test.
Results
Purification, and Conjugation of DnaK, OmpA and Tul4 Proteins of F.
tularensis SchuS4 to TMV
F. tularensis SchuS4 dnaK (FTT1269c), ompA (FTT0831c), and tul4 (FTT0901) genes were
expressed in E. coli as N-terminal 6X-His tagged proteins and purified by metal affinity chro-
matography. The purity of these recombinant proteins was confirmed by SDS-PAGE and west-
ern blot analysis using anti-His monoclonal antibodies. Bands of 70kDa, 47kDa and 17kDa
confirmed the identities of DnaK, OmpA and Tul4 proteins, respectively (Fig 3). Genetically
modified TMV which has a surface exposed Lysine was conjugated with purified DnaK, OmpA
and Tul4 proteins of F. tularensis SchuS4 collectively in a single reaction for generation of
TMV-monoconjugate vaccine (Fig 4A) or individually in multiple conjugation reactions to
generate TMV-multiconjugate vaccine (Fig 4B, 4C and 4D). The conjugation reaction was
anticipated to be complete once the higher molecular weight products were observed on
SDS-PAGE gels and the quantity of free recombinant protein in a TMV-protein mixture was
less than 10% of the unconjugated controls. Maximum conjugation efficiency was observed
after 2 hours of incubation marked by the presence of high molecular weight complexes and
disappearance of free proteins.
Multivalent Vaccine for Prevention of Tularemia
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Immunization of Mice with TMV-Multiconjugate Vaccine Induces
Antibody Responses Capable of Recognizing both Native and
Recombinant DnaK, OmpA and Tul4 Proteins
Since purification of recombinant proteins may alter their confirmation or may result in dena-
turation of immunogenic epitopes, we next investigated if vaccination of mice with TMV-mul-
ticonjugate vaccine generates an antibody response capable of recognizing native Francisella
DnaK, OmpA and Tul4 proteins. Mice immunized with the TMV-multiconjugate vaccine fol-
lowing immunization Schedule II in which mice were boosted by both the i.n. and s.c. routes
were bled on day 28 post-immunization. The pooled sera from TMV-multiconjugate vaccine
immunized mice specifically recognized DnaK, OmpA and Tul4 proteins in F. tularensis LVS
and SchuS4 lysates indicating that all the antigenic epitopes in immunizing proteins are intact
and are capable of recognizing native bacterial proteins (Fig 5A). Conversely, we also investi-
gated if vaccination of mice with live F. tularensis LVS induces antibody responses against
native DnaK, OmpA and Tul4 proteins that can react with the purified recombinant forms of
these three proteins. Our results show that sera from mice immunized with live F. tularensis
LVS recognized all three recombinant proteins similar to those observed for sera from mice
immunized with TMV-multiconjugate vaccine (Fig 5B).
Immunization with TMV-Monoconjugate Vaccine Generates Antibody
Response Predominated by IgG1 Antibodies
We first investigated the antibody response in mice that received TMV-monoconjugate vaccine
formulation in which all the three recombinant proteins were conjugated to a single TMV
virion, and received boosters only on day 7 and 14 (Schedule I). Mice were bled on day 28
post-immunization and antibody responses were determined. Higher levels of Francisella
specific total IgG levels were detected in TMV-monoconjugate vaccinated mice (Fig 6). Deter-
mination of IgG isotypes on day 28 post-immunization revealed that mice vaccinated with
TMV-monoconjugate vaccine induced higher IgG1 levels. However, very low to undetectable
levels of IgG2a and IgG2b antibodies were observed in this group of vaccinated mice (Fig 6).
Antigen specific ELISA indicated that antibodies were generated against OmpA, DnaK and
Tul4 proteins (Fig 7). Collectively, these results indicated that a weak antibody response pre-
dominated by a Th2 biased immune response is generated in mice immunized using Schedule I
vaccination regimen with TMV-monoconjugate vaccine formulation.
Fig 3. Expression and Purification of Recombinant DnaK, OmpA and Tul4 Proteins of F. tularensis SchuS4. Purification of recombinant OmpA, DnaK
and Tul4 proteins of F. tularensis SchuS4 proteins was confirmed by SDS-PAGE and western blot analysis using anti-His antibodies.
doi:10.1371/journal.pone.0130858.g003
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Immunization Schedule I with TMV-Multiconjugate Vaccine Generates
Stronger Antibody Responses than those Observed with
TMV-Monoconjugate Vaccine
We next examined antibody response generated following vaccination with TMV-multi
conjugate vaccine in which individual TMV-protein conjugates were blended in a multivalent
formulation. The vaccination schedule included booster immunizations on days 7 and 14 post-
immunization (Schedule I). The total IgG responses observed on days 14 (not shown) and 28
Fig 4. Conjugation of DnaK, OmpA and Tul4 Proteins of F. tularensis SchuS4 to TMV. Purified OmpA,
DnaK and Tul4 proteins were combined with purified TMV and incubated with EDC and NHS for 0, 30 min, 1,
or 2 hours as described in Methods section. Two μg of TMV or recombinant proteins DnaK, OmpA, Tul4 or
4 μg of the TMV-protein mixtures were resolved on an 8–16% SDS-PAGE gel to observe conjugation
products indicated by changes in the molecular masses of the starting materials. (A) Conjugation of DnaK,
OmpA and Tul4 to a single TMV virion to generate TMV-monoconjugate vaccine. The progress of
conjugation process was observed over a period of time: Lane M = Precision Plus Dual Color standard
(BioRad) Marker; Lane 1 = TMV-protein mix, 0 min; Lane 2 = TMV-protein mix, 30 min; Lane 3 = TMV-protein
mix,1 hour; Lane 4 = TMV-protein mix, 2 hours. (B, C, D) Kinetics of DnaK, OmpA and Tul4 TMV-protein
conjugations over a two hour incubation period to generate TMV-protein conjugates. The individual TMV-
protein conjugates were then admixed to generate TMV-multiconjugate vaccine. Lane M = Precision Plus
Dual Color standard (BioRad) Marker; Lane 1 = TMV; Lane 2 = Recombinant protein; Lane 3 = TMV-protein
mix, 0 hour; Lane 4 = TMV-protein mix, 1 hour; Lane 5 = TMV-protein mix, 2 hours. In all cases, 2 hour time
points were used for scale-up and vaccine preparation. Solid arrows indicate TMV-protein conjugate(s),
dashed arrows indicate free TMV or free proteins.
doi:10.1371/journal.pone.0130858.g004
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were much higher than those observed with the TMV-monoconjugate vaccine (Fig 6). IgG
isotype profiles were also different in TMV-multiconjugate vaccine than those observed
for TMV-monoconjugate vaccine immunized mice. Higher levels of Francisella specific IgG2a
and IgG2b antibodies were observed in immunized mice. However, as observed for TMV-
monoconjugate vaccinated mice, higher levels of IgG1 antibodies were also observed in
Fig 5. Immunization of Mice with TMV-Multiconjugate Vaccine Induces Antibody Responses Capable
of Recognizing both Native and Recombinant OmpA, DnaK and Tul4 Proteins. (A) Serum collected on
day 28 post-immunization from C57BL/6 mice immunized with TMV-multiconjugate vaccine (Schedule II) was
pooled (n = 4) and blotted against F. tularensis LVS and SchuS4 lysates. (B) Pooled serum from C57BL/6
mice (n = 4) immunized either with TMV-multiconjugate vaccine, or 100 CFU of F. tularensis LVS were
collected on day 28 post immunization and blotted against purified recombinant OmpA, DnaK and Tul4
proteins. Sera frommice inoculated with TMV alone were used as controls.
doi:10.1371/journal.pone.0130858.g005
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TMV-multiconjugate vaccinated mice (Fig 6). The levels of OmpA and DnaK specific antibod-
ies were significantly higher in TMV-multiconjugate vaccinated mice than those observed for
TMV-monoconjugate vaccinated mice. However, no differences in levels Tul4 specific antibod-
ies were observed in groups of mice vaccinated with these two vaccine formulations (Fig 7).
Collectively, these results indicate that TMV-multiconjugate vaccine formulation is a better
vaccinogen than the TMV-monoconjugate vaccine however, similar to the latter vaccine for-
mulation, generates an immune response predominated by IgG1 antibodies.
An Aggressive Immunization with TMV-Multiconjugate Vaccine does not
Further Enhance Antibody Response
We further investigated if an aggressive immunization schedule consisting of TMV-multi con-
jugate formulation administered by both the i.n. and s.c. routes with multiple booster vaccina-
tions (Schedule II) improves the antibody response compared to the other two vaccination
strategies. It was observed that the total IgG and IgG1 antibody responses did not differ from
mice vaccinated with TMV-multiconjugate vaccine using Schedule I (Fig 8). However, the lev-
els of antibody isotypes IgG2a and IgG2b were in fact significantly higher in mice vaccinated
with the TMV-multiconjugate vaccine receiving Schedule I than those receiving Schedule II
vaccinations (Fig 8). We further investigated if there are any differences in levels of antibodies
generated against native proteins of F. tularensis SchuS4 and F. tularensis LVS. No differences
in IgG, IgG1, IgG2a and IgG2b antibody levels were observed when ELISAs were performed
using F. tularensis SchuS4 and LVS lysates (Fig 8). These results indicate that similar to the
results obtained with western blot analysis, antibodies from TMV-multiconjugate vaccine are
equally capable of recognizing native proteins of both F. tularensis SchuS4 and F. tularensis
LVS. The group of mice receiving Schedule II of TMV-multiconjugate vaccine showed signifi-
cantly higher titers of OmpA antibodies, while titers of DnaK and Tul4 antibodies were similar
to those receiving Schedule I vaccination with TMV-multiconjugate vaccine (Fig 9).
Protective Efficacy of TMV-Conjugate Vaccine
We investigated the protective efficacy of the TMV-monoconjugate and TMV-multiconjugate
vaccine by vaccinating mice using immunization schedules I and II as described in Fig 2.
Mice were immunized with TMV-monoconjugate vaccine using only immunization schedule
I; while both schedule I and II were used for TMV-multiconjugate vaccine. Mice were chal-
lenged i.n. with 10×LD100 dose of F. tularensis LVS on day 28 post-primary immunization and
observed for a period of 21 days for morbidity and mortality. Only 25% of mice immunized
with TMV-monoconjugate vaccine survived the challenge while 100% of control mice receiv-
ing TMV succumbed to infection by day 11 post-challenge. Measurement of body weights
showed an identical pattern of body weight loss between TMV-monoconjugate vaccinated and
TMV control groups till day 7 post-challenge after which mice destined for survival started to
recover their body weights (Fig 10A and 10B). 40% of mice survived the challenge and started
to regain their body weights by day 8 post-challenge in the group of mice that received TMV-
multiconjugate vaccine using Schedule I vaccination regimen. All the control mice progres-
sively continued to lose weight and succumbed to challenge (Fig 10C and 10D). The pattern of
Fig 6. Antibody Responses in Mice Immunized with TMV-Monoconjugate and TMV-Multiconjugate Vaccines using Schedule I of Immunization.
Francisella specific total IgG, IgG1, IgG2a and IgG2b levels on day 28 in serum samples of C57BL/6 mice immunized with TMV-monoconjugate and TMV-
multiconjugate vaccine using Schedule I were determined using an ELISA. Serum samples obtained from naïve mice or those inoculated with TMV alone
were used as controls. The data are represented as Mean ±S.D. of absorbance values measured at 450nm. Table shows comparison of antibody titers
between groups of mice vaccinated with these vaccine formulations.
doi:10.1371/journal.pone.0130858.g006
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Fig 7. OmpA, DnaK and Tul4 Specific Antibody Responses in Mice Immunized with TMV-Monoconjugate and TMV-Multiconjugate Vaccines using
Schedule I of Immunization. F. tularensis SchuS4 recombinant proteins OmpA, DnaK and Tul4 specific IgG antibody levels on day 28 in serum samples of
C57BL/6 mice immunized with TMV-monoconjugate and TMV-multiconjugate vaccine using Schedule I were determined by ELISA. Serum samples
obtained from naïve mice or those inoculated with TMV alone were used as controls. The data are represented as Mean ±S.D. of absorbance values
measured at 450nm. Table shows comparison of antibody titers between groups of mice vaccinated with these vaccine formulations.
doi:10.1371/journal.pone.0130858.g007
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survival and body weight loss of mice receiving TMV-multiconjugate vaccine with Schedule II
was similar to that observed for mice vaccinated with Schedule I regimen, however 50% of the
vaccinated mice survived the challenge (Fig 10E and 10F). Additional booster vaccinations by i.
n. and s.c. routes in Schedule II only slightly improved the level of protection in this group of
vaccinated mice. Collectively, these results demonstrated that Francisella proteins conjugated
to TMV when used as vaccine induce protective immune response in mice. These results also
indicated that TMV-monoconjugate vaccine in which all the three recombinant proteins
OmpA, DnaK and Tul4 of F. tularensis conjugated to a single TMV virion serves as a poor vac-
cinogen. On the other hand, the vaccine formulation that contains a multivalent blend of all
the three proteins conjugated individually to TMV induces a superior protective immune
response that can marginally be improved further by increasing number of booster vaccina-
tions by s.c. route.
Discussion
The possibility of using F. tularensis as a bioterror agent has renewed attention towards F.
tularensis research and to develop a licensable vaccine for effective prevention of tularemia.
The tularemia vaccine development research has largely been focused on development of live
attenuated or inactivated tularemia vaccines. However, concerns about their efficacy and safety
have halted the progress. A recent study confirms this notion and reported a variant of F. tular-
ensis LVS which is 100 times lethal than the standard ATCC strain indicating that, as feared, F.
tularensis LVS may revert back to its virulent form [46]. Recombinant subunit vaccines obvi-
ously have potential safety advantages over inactivated or live attenuated vaccines.
Ongoing studies for subunit vaccine development have identified a number of F. tularensis
antigens that are capable of inducing a partial protective immune response [47,48,49,50,51].
The possible explanation for limited protective efficacy of these subunit vaccines could be that
a single protein or combinations of proteins used in vaccine formulations were not sufficient to
induce an efficient protective immune response. Another shortcoming appeared to be the
availability of a suitable platform for simultaneous delivery of antigens in a consistent fashion.
It has been shown that the protective efficacy improves when multiple antigens are used in vac-
cine formulations [52,53,54]. However, the biggest challenge thus far in the development of
multivalent subunit vaccines has been the availability of suitable approaches for consistent
preparation and efficient delivery of multiple antigens through mucosal route.
The goal of this study was to explore vaccine potential of a multivalent subunit vaccine
against tularemia using an efficient TMV based delivery platform. The premise behind utilizing
a novel TMV-conjugated vaccination strategy is based on the proven efficacy of TMV vaccines
in stimulating robust immune response without the requirement of an additional adjuvant
[29]. In order to provide a proof-of-concept and feasibility of TMV as a carrier for F. tularensis
proteins, we used purified recombinant proteins OmpA, DnaK and Tul4 from F. tularensis
SchuS4 for conjugation studies and determined the vaccine potential of TMV-F. tularensis pro-
tein conjugates. Two different vaccine formulations consisting either of all three F. tularensis
proteins conjugated to a single TMV virion (TMV-monoconjugate vaccine); or a mixture con-
sisting of each protein individually conjugated to TMV (TMV-multiconjugate vaccine) were
Fig 8. Antibody Responses in Mice Immunized with TMV-Multiconjugate Vaccines using Schedule I and II of Immunization. Francisella specific total
IgG, IgG1, IgG2a and IgG2b levels on day 28 in serum samples of C57BL/6 mice immunized with TMV-multiconjugate vaccine using Schedule II were
determined by ELISA. The plates were coated with F. tularensis SchuS4 or LVS lysates. Serum samples obtained from naïve mice or those inoculated with
TMV alone were used as controls. The data are represented as Mean ±S.D. of absorbance values measured at 450nm. The comparisons are shown with the
data obtained frommice immunized with TMV-multiconjugate vaccine using schedule I (shown in Fig 6). Table shows comparison of antibody titers between
groups of mice vaccinated with Schedule I and II vaccination regimens.
doi:10.1371/journal.pone.0130858.g008
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Fig 9. OmpA, DnaK and Tul4 Specific Antibody Responses in Mice Immunized with TMV-Multiconjugate Vaccines using Schedule I and II of
Immunization. F. tularensis SchuS4 recombinant proteins OmpA, DnaK and Tul4 specific IgG, antibody levels on day 28 in serum samples of C57BL/6 mice
immunized with TMV-multiconjugate vaccine using Schedule II were determined by ELISA. The plates were coated with recombinant F. tularensis SchuS4
proteins. Serum samples obtained from naïve mice or those inoculated with TMV alone were used as controls. The data are represented as Mean ±S.D. of
absorbance values measured at 450nm. The comparisons are shown with the data obtained frommice immunized with TMV-multiconjugate vaccine using
schedule I (shown in Fig 7). Table shows comparison of antibody titers between groups of mice vaccinated with Schedule I and II vaccination regimens.
doi:10.1371/journal.pone.0130858.g009
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used. Both the vaccine formulations resulted in generation of antibodies against all three
recombinant proteins. Most importantly, these antibodies recognized native Francisella as well
as recombinant proteins. These results indicate that the purification or conjugation procedures
did not alter conformation of the epitopes recognized in native OmpA, DnaK or the Tul4
proteins.
When immune responses were compared between mice receiving TMV-monoconjugate
and TMV-multiconjugate vaccine using a similar vaccination regimen (Schedule I), a weaker
antibody response was observed in mice vaccinated with monoconjugate formulation. These
results indicate that conjugating all proteins to a single TMV virion is not an ideal approach for
development of a TMV-based tularemia vaccine. The poor antibody response could be due to
preferential conjugation of one of the three proteins in the conjugation mix or due to antigenic
competition. The antibody responses observed against OmpA and DnaK proteins does support
this notion. It was observed that TMV-monoconjugate vaccinated mice induced antibody
response against Tul4 protein were similar to those observed for TMV-multiconjugate vaccine
formulations however, the response against OmpA and DnaK were significantly lower than
that observed for the latter vaccine formulation (Fig 7). The binding capacity of each of these
proteins to TMV was not determined in the present study. However, these results do point to
the fact that Tul4 due to its smaller size may have a preferential binding to the surface of TMV
than OmpA or DnaK proteins. Moreover, the immune response was predominated by IgG1
antibodies and no IgG2a or IgG2b responses were observed in mice vaccinated with TMV-
monoconjugate vaccine. These results indicate generation of a predominantly Th2 biased
immune response in this group of vaccinated mice. Contrary to what was observed for TMV-
monoconjugate vaccinated mice, the TMV-multiconjugate vaccinated mice mounted a very
strong Francisella specific total IgG response and the titers went up from days 14 to 28 post-
immunization (not shown). Although, IgG1 was the most predominant antibody isotype,
higher levels of IgG2a and IgG2b antibodies were also detected in this group of immunized
mice. It is noteworthy that both the IgG2a and IgG2b antibodies have been shown to be protec-
tive against F. tularensis infection [55,56]. Collectively, these results indicate that conjugating
each protein individually to TMV and then blending them in equimolar concentration to gen-
erate a multiconjugate composition is an ideal approach for the development of a TMV-based
tularemia vaccine.
We further investigated if an enhanced immune response can be generated following an
aggressive vaccination regimen with the TMV-multiconjugate vaccine. We administered
booster vaccinations by alternating i.n. and s.c. routes. The intent was to induce potent sys-
temic as well as local mucosal immune response by administering vaccine by both i.n. and s.c.
routes (Schedule II). However, the immune responses did not differ from those observed in
mice receiving only two booster vaccines (Schedule I). We speculate that the failure to observe
further amplification following an aggressive vaccination could be due to an excessive antigenic
overload. When vaccinated mice were challenged intranasally with 10LD100 dose (1x10
5 CFU)
of Ft LVS, corresponding to the weak antibody response only 25% mice were protected with
TMV-monoconjugate vaccine formulation. However, with multiconjugate formulation the
protection levels were nearly 40% and an aggressive immunization marginally improved the
protection to 50%. Collectively, these results demonstrate that TMV can be used as a carrier for
Fig 10. Protective Efficacy of TMV-Conjugate Vaccine. (A) C57BL/6 mice (N = 8 per group) immunized with TMV-monoconjugate vaccine; (C) with TMV-
multiconjugate vaccine (schedule I) or (E) with TMV-multiconjugate vaccine (Schedule II) were challenged i.n. with 10xLD100 of F. tularensis LVS on day 28
post-immunization. Mice vaccinated with TMV alone were used as controls. Challenged mice were observed for morbidity and mortality for a period of 21
days post-challenge. The survival results are expressed as Kaplan-Meier survival curves and statistical analysis was performed using Log-rank test. (B, D
and F) Body weight of the challengedmice at the indicate time points. The data are represented as Mean ± S.D.
doi:10.1371/journal.pone.0130858.g010
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effective delivery of multiple F. tularensis antigens. The TMV-conjugate vaccine is safe and
multiple doses can be administered in mice without any adverse reactions and immunization
with F. tularensis antigens conjugated individually and blended in a multivalent composition
induce a more potent immune response than the formulation in which all of the three proteins
are conjugated to a single TMV virion. Most importantly immunization with TMV-conjugated
F. tularensis proteins can protect mice against lethal doses of F. tularensis LVS.
In conclusion, this study provides a proof-of-concept that TMV can serve as a suitable plat-
form for simultaneous delivery of multiple protective antigens of F. tularensis. Future studies
to improve the level of protection would require generation of TMV-multiconjugate vaccine by
incorporating additional immunoprotective antigens of F. tularensis and inclusion of suitable
adjuvant(s) to generate potent humoral and cell-mediated immune responses and induce long-
lasting immunity against tularemia caused by F. tularensis SchuS4 strain.
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